The phase 3 KEYNOTE-630 trial has begun enrolling patients with high-risk, locally advanced cutaneous squamous cell carcinoma (cSCC) to evaluate the curative potential of PD-1 inhibitor pembrolizumab.
Despite major progress in treating metastatic clear cell renal cell carcinoma, metastatic non-clear cell renal cell carcinoma remains poorly understood.
A breast oncologist’s take on three new treatment modalities for a difficult-to-treat cancer.
Data from 15 centers in the U.S. and Europe indicate that immunosuppressive therapy should be used more frequently in patients with myelodysplastic syndromes.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A multicenter team studied the safety of immunotherapy atezolizumab in patients with myelodysplastic syndrome who had either failed or never received conventional HMA therapy.
The list of cancer immunotherapy drugs is growing, along with immune-related adverse events (IRAEs). ACR 2018 offers several sessions to update rheumatology providers on this fast-developing topic.
Immunotherapy hasn’t benefited breast cancer patients — yet. Breast medical oncologist Megan Kruse, MD, explains how that may be changing.
Investigating tumor mutational burden, specific driver mutations, immune-related RNA expression data and various clinicopathologic features from 479 tumors to find correlations with clinical characteristics and outcomes.
By now most rheumatologists are aware that checkpoint inhibitors are capable of unleashing a wide array of autoimmune and autoinflammatory adverse events within virtually every organ system. These complications have posed new challenges to all practitioners.
Individuals with clinically unapparent HBV and concomitant immune-mediated inflammatory diseases (IMIDs) (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease and others) are particularly vulnerable to HBV reactivation when immunosuppressed.